Acute Leukemias

Acute Leukemias

A collection of features and news articles published in ASH Clinical News related to acute leukemias.

On location

Non-Engineered T Cells to Prevent or Treat Relapse in Post-Transplant AML/MDS

Infusion with “non-engineered” adoptive T-cell products induced responses in select patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) who had undergone allogeneic...
On location

RADIUS: Midostaurin Reduces Post-Transplant Relapse Risk in FLT3-Mutated AML

Post-transplant maintenance therapy with midostaurin was safe and reduced relapse risk in patients with FLT3-mutated acute myeloid leukemia (AML), according to findings from the...
On location

Prognostic Significance of Post-Transplant MRD Varies Based on Conditioning Regimen in ALL

Assessment of measurable residual disease (MRD) prior to allogeneic hematopoietic cell transplantation (alloHCT) is an established important prognostic factor in patients with acute lymphocytic...

Medicare Poised to Cover CAR T-Cell Therapy

Medicare may soon offer coverage of chimeric antigen receptor (CAR) T-cell therapy for patients with cancer, but with considerable restrictions that aim to rein...

Dasatinib Granted Approval for Pediatric Indication

The FDA expanded the indication of dasatinib, a second-generation tyrosine kinase inhibitor, to include the treatment of pediatric patients (≥1 year of age) with...
WIB_icon

Evaluating Midostaurin Plus Intensive Chemotherapy in Older Patients With AML

Midostaurin plus intensive chemotherapy, followed by allogeneic hematopoietic cell transplantation (alloHCT) and single-agent midostaurin maintenance therapy, was improved survival outcomes in patients with newly...

FDA Approves Calaspargase Pegol-mknl for Acute Lymphocytic Leukemia

The FDA approved calaspargase pegol-mknl, an asparagine-specific enzyme, for the treatment of pediatric and young adult patients (ages 1 month to 21 years) with...

Predicting Response to Alvocidib in Patients With Relapsed/Refractory AML

The CDK9 inhibitor alvocidib induced a high rate of responses in patients with relapsed or refractory acute myeloid leukemia (AML) who had MCL1-dependent disease,...

An MRD-Guided Azacitidine Treatment Strategy Delays Hematologic Relapse in MDS and AML

According to results from the phase II RELAZA2 trial, minimal residual disease (MRD)–guided treatment with the hypomethylating agent azacitidine delayed hematologic relapse in patients...
WIB_icon

A Pediatric Regimen Is Effective for Adolescents and Young Adults With ALL

Adolescents and young adults (AYAs) with newly diagnosed acute lymphocytic leukemia (ALL) who received a pediatric-inspired regimen had better survival outcomes than historical controls,...
Advertisement

Current Issue

August 2019, Volume 5, Issue 10

August 2019, Volume 5, Issue 10

This issue features a debate about gun control as a health care issue, a look at blood services in Israel and Palestine, and more.